{"id":5178,"date":"2026-10-16T10:51:22","date_gmt":"2026-10-16T10:51:22","guid":{"rendered":"https:\/\/nhdbio.com\/?p=5178"},"modified":"2026-10-16T10:51:22","modified_gmt":"2026-10-16T10:51:22","slug":"tirzepatide-176-week-prediabetes-diabetes-incidence","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/ar\/tirzepatide-176-week-prediabetes-diabetes-incidence\/","title":{"rendered":"\u200fTirzepatide \u0639\u0646\u062f 176 \u0623\u0633\u0628\u0648\u0639\u064b\u0627: \u0642\u0631\u0627\u0621\u0629 \u0646\u062a\u0627\u0626\u062c \u062f\u0627\u0621 \u0627\u0644\u0633\u0643\u0631\u064a"},"content":{"rendered":"
\n

Tirzepatide at 176 Weeks: Reading the Diabetes Results<\/h2>\n

Understand the prediabetes subgroup, diabetes incidence and absolute differences in the long-term SURMOUNT-1 analysis.<\/p>\n

\"Tirzepatide
\u0631\u0633\u0645 \u062a\u0648\u0636\u064a\u062d\u064a \u062a\u062d\u0631\u064a\u0631\u064a\u060c \u0648\u0644\u064a\u0633 \u0635\u0648\u0631\u0629 \u062a\u062c\u0631\u064a\u0628\u064a\u0629.<\/figcaption><\/figure>\n

Why this analysis concerns 1032 people<\/h3>\n

SURMOUNT-1 enrolled 2539 participants with obesity, including 1032 who also had prediabetes. This long-term analysis concerned the latter subgroup. Its risk figures should not be applied to all healthy people, all people with diabetes or the entire initial trial population.<\/p>\n

Diabetes incidence at 176 weeks<\/h3>\n

The paper reported a type 2 diabetes diagnosis in 1.3% of pooled tirzepatide groups versus 13.3% with placebo. The figure uses a zero-based vertical axis. These are observed proportions for the study population, not individual predictions or a complete description of the follow-up trajectory.<\/p>\n

\"Tirzepatide:
Obesity with prediabetes, n=1032; pooled tirzepatide doses. Not general-population risk or evidence for a catalog product.<\/figcaption><\/figure>\n
\n\n\n\n\n\n\n
Tirzepatide: diabetes incidence at 176 weeks<\/caption>\n
Condition<\/th>\nIncidence (%)<\/th>\n<\/tr>\n<\/thead>\n
\u062a\u064a\u0631\u0632\u0628\u0627\u062a\u064a\u062f<\/th>\n1.3%<\/td>\n<\/tr>\n
\u062f\u0648\u0627\u0621 \u0648\u0647\u0645\u064a<\/th>\n13.3%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

Absolute differences and modeled risks differ<\/h3>\n

Subtracting 1.3% from 13.3% gives an absolute difference of 12.0 percentage points. A relative comparison calculated from these proportions is not the same statistic as a modeled hazard ratio. Do not merge a hazard ratio, diabetes incidence and weight-change percentage into one undefined effectiveness rate.<\/p>\n

Weight and later follow-up use different endpoints<\/h3>\n

At week 176, mean weight changes were \u221212.3%, \u221218.7% and \u221219.7% across the tirzepatide dose groups, versus \u22121.3% with placebo. After a further 17 weeks off treatment, diabetes proportions were 2.4% and 13.7%. Keep endpoints and timepoints matched when comparing results.<\/p>\n

Include the adverse-event context<\/h3>\n

The paper reports gastrointestinal events as common adverse events, mostly mild to moderate and occurring mainly during dose escalation in the first 20 weeks. Individual applicability requires a complete benefit\u2013risk assessment. This explanation does not provide a personal medication plan.<\/p>\n

Clinical findings do not validate a catalog batch<\/h3>\n

The Tirzepatide page supports research-material and quotation enquiries. Clinical-trial formulations and catalog materials require separate identification. A shared name alone does not make trial outcomes evidence of a particular catalog batch's efficacy or safety.<\/p>\n

\u0645\u0631\u0627\u062c\u0639<\/h3>\n